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 Legislative Mandate 
 
The following report is hereby issued pursuant to Section 25A of Chapter 112 of the 
Massachusetts General Laws, as inserted by Chapter 159 of the Acts of 2014, as follows:  
 
Section 25A. The board shall submit an annual report to the department of public health, the joint 
committee on public health and the joint committee on health care financing on or before 
December 31. The report shall detail the investigatory and disciplinary actions conducted by the 
board and shall detail: (1) each Complaint received by the board or initiated by the board; (2) 
the date of the Complaint; (3) the violation alleged; (4) the name of any state or federal agency 
that collaborated with the Investigation; (5) the summary of the final decision of the board to: (i) 
dismiss the Complaint, (ii) impose an informal sanction or penalty, (iii) impose a formal sanction 
or penalty or (iv) amend a previously issued sanction or penalty; and (6) whether the board 
reported the result of its Investigation to another state board, federal agency or external entity. 
 
All relevant data collected and analyzed under subsections (b) to (e), inclusive, of section 39D 
shall be summarized and included in the report. The report shall be made available, including by 
electronic means, to the public and all hospitals, pharmacies and health care providers doing 
business in the commonwealth. Said report shall be posted on the department of public health's 
website. 
 
Executive Summary 
 
The enactment of Chapter 159 of the Acts of 2014, An Act Relative to Pharmacy Practice in the 
Commonwealth, brought with it many new requirements and opportunities for the Board of 
Registration in Pharmacy (Board). This Report, entitled “Investigatory & Disciplinary Actions 
Conducted by the Board of Registration in Pharmacy” is intended to track all Complaints that 
moved through the Board from December 1, 2017 to December 1, 2018.  This is the sixth annual 
Report as directed by the Act. 
 
Each year the Board must track and report (1) each Complaint received by the Board or initiated 
by the Board; (2) the date of the Complaint; (3) the violation alleged; (4) the name of any state or 
federal agency that collaborated with the Investigation; (5) the summary of the final decision of 
the Board to: (i) dismiss the Complaint, (ii) impose an informal sanction or penalty, (iii) impose a 
formal sanction or penalty or (iv) amend a previously issued sanction or penalty; and (6) whether 
the Board reported the result of its Investigation to another state board, federal agency or external 
entity.  
 
The Board and Board staff have continued to work diligently to conduct Investigations and 
process cases expeditiously.  In 2018, much progress has been made including the following: 
 
 The continued expedited processing of files; 
 The continued heightened monitoring of drug losses and other drug violations; 
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 An increase in dismissed Complaints due to the continued implementation of Just Culture 
through the use of voluntary anticipatory continuing education credits in lieu of discipline 
for specified Complaint types; 
 The continued collaboration with local, state and federal agencies; 
 A continued robust field presence uncovering regulatory violations and inspectional 
deficiencies; and 
 A continued focus on information gathering at the Investigation level prior to initiating 
formal Complaints. 
 
Since the first annual report in 2013, the processes put in place have allowed the Board and Board 
staff to move cases through the system with accurate information at an accelerated pace.  A 
thorough Investigation and well written report allows the Board to resolve these cases quickly and 
efficiently.  The goal is to continue to fine-tune the Board’s processes and procedures and ensure 
that quality improvement is monitored, continuing in 2019 and beyond. 
 
Introduction 
 
Following the 2012 multi-state meningitis outbreak that was attributed to products from a 
Massachusetts-based pharmacy, legislation containing sweeping pharmacy practice reform was 
signed into law. Immediately after the outbreak, the Board began implementing regulatory and 
administrative reforms to improve oversight of the compounding pharmacy industry. Specifically, 
the Board staff instituted new or updated existing administrative procedures, including priorities 
for Complaint Investigations; timelines and guidelines for standard Investigation activities; 
guidelines for handling evidence and chain of custody logs; and processes for Complaint intake 
and triage. Additionally, Board staff developed new policies and procedures, including managing 
communication about abnormal test results; managing above action limit
1
 environmental 
monitoring results; reporting of defective drug preparations, pharmacy retail drug store closures; 
and handling incoming reports of theft or loss of controlled substances. These efforts helped the 
Board achieve its goal of enhanced oversight of the compounding pharmacy industry, as well as 
traditional retail pharmacies. 
 
This annual report tracks all pharmacy Complaints that were either pending, received, initiated, or 
opened during the period of December 1, 2017 through December 1, 2018. 
 
Case Flow Overview 
An overview of the Board’s case flow is provided to offer context to this report.2 The Board 
receives initial Complaints alleging regulatory violations or other misconduct against a licensee. 
At a weekly pharmacy triage meeting, Board staff determines whether the allegations, if true, 
assert a violation of laws or regulations governing the practice of pharmacy by the particular 
licensee, and take one of three actions: 
                                                 
1 The level which requires a pharmacy engaged in sterile compounding to take remedial measures. 
2
 See Appendix A:  Case Flow Diagram. 
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1. If they determine that the facts alleged, if true, would not constitute a violation, Board staff 
will close the matter. 
2. If they determine that the facts alleged do constitute a violation and that there is clear evidence 
supporting the allegations, Board staff open a formal disciplinary Complaint (Complaint). 
3. If further information is needed to make the determination, Board staff open an Investigation. 
 
In the case of both Complaints and Investigations, Board staff conducts further investigation as 
necessary. If the evidence gathered in an Investigation clearly supports a violation, the 
Investigation may be immediately converted into a Complaint. If the Investigation does not yield 
clear evidence supporting a violation against a particular licensee, the Investigation is presented to 
the Board to determine if a Complaint should be opened or the matter should be closed. 
 
As part of the Investigation, the investigator contacts the licensee for a response to the allegations. 
The investigators also obtain evidence, as available, from complainants
3
 and other witnesses. 
When the Investigation is complete, the investigator writes a report. The report is then reviewed 
by the Director of Pharmacy Investigations to ensure accuracy and completeness. 
 
Next, the Director of Pharmacy Investigations determines whether the Complaint will be 
presented to the Board or go to the Board Delegated Review (BDR) committee.
4
 The BDR has 
authority to dispose of Investigations or Complaints that fall under Board-specified criteria. 
 
If the Complaint is outside of the BDR criteria, the Complaint will be slotted for review on a 
Board meeting agenda and subsequently presented to the Board. Following the Board meeting 
review, the Board members may take the following actions: (1) dismiss the matter; (2) request 
further Investigation; (3) authorize commencement of disciplinary proceedings; and/or (4) 
authorize terms for resolution of the Complaint by consent agreement. 
 
In reviewing the data presented in Appendices B, C, and D, you will notice that the length of 
Investigation and length of time until resolution of these cases may vary considerably. Various 
factors may contribute to the length of a case including complexity; availability of evidence or 
witnesses; concurrent criminal matters where Board cases may be delayed or placed on hold; 
lengthy administrative hearings; appeal of final decisions. Appendices E through Q summarize 
relevant information captured in the overall data. 
 
Data Structure 
The data is separated into three (3) sections: 
1. Formal Complaints; 
2. Investigations; and 
3. Preventable Medication Errors. 
 
For all cases listed, the report indicates the number assigned to each case, the name and license 
number of the licensees involved, the violation alleged,
5
 and, if the case is beyond the 
                                                 
3
 Complainant: a person who makes a formal charge in an administrative proceeding or court saying that someone has 
done something wrong. 
4
 The BDR consists of at least one Board member and at least the following Board staff: (1) the Executive Director or 
their designee; (2) Director of Compliance or their designee; and (3) Board Counsel. 
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Investigation stage, the name of any local, state or federal agency that collaborated in the 
Investigation. For each of the cases handled by the Board during the above-listed time frame, a 
chronological account of the Board actions taken is indicated as follows: 
 
 For Complaints, the date the Investigation was opened, the date it was sent to the Board 
for Board action, the date it went to Board Counsel, the date it was sent to Prosecution, 
and the date the case was closed are included.  
o If the case is closed, the result is provided.  
o If the result was discipline on a license, the report indicates if the discipline was 
externally reported.  
o If a “not applicable (N/A)” is noted, it indicates that the Investigation or Complaint 
did not proceed to that stage or does not yet have a final decision. 
 
 For Investigations, the date the Investigation was opened, the date it was closed, and the 
date any Complaint was opened as a result of the Investigation are included. Associated 
Complaints that are related, but opened prior to the Investigation or in relation to the 
Investigation are also included in this report. An Investigation cannot result in discipline, 
because it would first have to be converted to a Complaint, and for that reason, no results 
of Investigations have been reported externally. 
 
 The report of Preventable Medication Errors details all available information for 
Complaints and Investigations where the alleged violation was related to a medication 
error. For each medication error, the report indicates a synopsis of the medication error.  
Redundant errors are typically companion cases related to the same medication error, for 
all responsible licensees (pharmacy, pharmacist, pharmacy intern, pharmacy technician, 
etc.). 
 
This Report is comprised primarily of data that has been collected and analyzed from December 
1, 2017 through December 1, 2018. The data presented in the Excel spreadsheets in Appendices 
B, C, and D contain all of the information that has been collected. Appendices E through Q 
contain an analysis of the information as well as charts to show a quick examination of the data, 
easily compare data sets and emphasize trends. 
 
Conclusion 
 
The systematic changes and improvements that have been put in place over the last six years 
reflect a Board that has policies and procedures that are clear, effective, and efficient. In addition, 
these changes also support a group of pharmacy investigators that continue to have a commanding 
field presence which they utilize to educate the pharmacy community on compliance standards, 
ultimately leading to improved compliance with pharmacy laws and regulations. 
 
                                                                                                                                                               
5
 Violations marked “Serious Reportable Event” pertains to a pharmacy’s requirement to report to the Board any 
improper dispensing of a prescription drug that results in serious injury or death. Violations marked “Other” are 
instances that do not fall under typical categories in the licensure database. Each year, the files in this category are 
reviewed to determine if new categories need to be established. 
7 
 
This report shows that the field presence of the pharmacy investigators and the implementation of 
controlled substance loss policy 16-02 have contributed to increased compliance with statutes, 
regulations, and policies.  This increased compliance, in conjunction with the completion of 
backlogged complaint volume from previous years and an efficient investigation process, has 
resulted in an overall decrease in case volume.  
 
This report details all formal Complaints and Investigations that were pending, received, initiated, 
or opened by the Board during the period of December 1, 2017 through December 1, 2018. 
Significant progress has been made, including the following: 
 
 In 2018, Board staff continued the efficient processing system established in 2014. 
Overall, the data depicts that the high rate of case closures established in 2014 was 
maintained in 2018. 
 The Board continued to process cases expeditiously in 2018, resulting in a 49.8% increase 
in case closures since 2013. 
 Board staff continued to encourage self-reports of continuing education deficiencies 
(classified as “Regulatory Violations”), resulting in an increase in Investigations related to 
these events. 
 Investigators continue to pay close attention to the reports of drug losses, record keeping 
discrepancies and diversions, resulting in an increase of “Drug Violations” Complaints 
and surpassing the volume of the historical leader, “Failure to Fill RX Properly” 
Complaints. 
 A continued field presence in 2018 uncovered regulatory violations and inspectional 
deficiencies resulting in formal Complaints.   
 The Board and staff continue to forge strong relationships with our local, state and federal 
partners and will collaborate on cases where doing so is in the best interest of public 
health and safety. 
 
As the Board and staff move forward, they intend to continue monitoring and making quality 
improvements in the Investigation and processing of formal Complaints and Investigations. This 
allows the Board to make informed and expeditious decisions on the numerous Complaints that 
are received each year; all with the primary goal of protecting the health, safety and welfare of the 
public. 
 
Appendix A:  Case Flow Diagram 
Discipline/Consent Agreement 
 
 
Appendix B:  Formal Complaint Data 
 
Please see separate Excel spreadsheet data. 
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Appendix C:  Investigation Data 
 
Please see separate Excel spreadsheet data. 
11 
 
Appendix D:  Medication Error Data 
 
Please see separate Excel spreadsheet data. 
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Appendix E:  Investigation Status Types 
 
 
 
Status 2013 2014 2015 2016 2017 2018 
Open 63 31 74 69 61 29 
Pending Board 52 50 26 42 43 31 
Pending Further Investigation 0 0 1 20 0 0 
Pending Legal 0 2 2 2 3 0 
Closed 76 136 144 211 195 215 
Total 191 219 247 344 302 275 
 
 
What this means:  The total number of active Investigations in 2018 decreased since 2017. This is 
still an increase from prior years.  Investigators work diligently to obtain evidence, statements, 
and write Investigation reports to get the information to the Board as quickly as possible, resulting 
in a decrease of pending Investigations.  The Board continues to consistently hear most cases that 
are scheduled to be heard during each Board meeting. 
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Appendix F:  Investigation Dispositions 
 
Disposition 2013 2014 2015 2016 2017 2018 
Resulting in Complaint 24 21 35 41 46 17 
Closed 43 109 109 170 195 198 
 
What this means:  Due to the decreased volume of files processed in 2018 by investigators and the 
Board, the total number of Investigations resulting in, or associated with, a Complaint, decreased.   
This may be a result of the Board’s goal to continue implementation of a Just Culture.6  
Investigations classified under the Investigation type “Failure to Fill Rx Properly” are 
increasingly sent to Board for review as Investigations rather than Complaints.  This allows the 
Board to make the determination of whether or not a complaint is necessary.
                                                 
6
 A Just Culture recognizes that individual practitioners should not be held accountable for system failings over 
which they have no control.  A Just Culture also recognizes many individual or “active” errors represent predictable 
interactions between human operators and the systems in which they work.  However, in contrast to a culture that 
touts “no blame” as its governing principle, a Just Culture does not tolerate conscious disregard of clear risks to 
patients or gross misconduct (e.g., falsifying a record, performing professional duties while intoxicated).  Excerpted 
from: Marx D. Patient Safety and the “Just Culture”: A Primer for Health Care Executives.  New York, NY: 
Columbia University; 2001.  Available at: 
http://www.safer.healthcare.ucla.edu/safer/archive/ahrq/FinalPrimerDoc.pdf 
0
50
100
150
200
250
Resulting in Complaint Closed
N
u
m
b
e
r 
o
f 
In
v
e
s
ti
g
a
ti
o
n
s
 
Dispositions 
Investigation Dispositions 
2013
2014
2015
2016
2017
2018
14 
 
Appendix G:  Most Common Investigation Types 
 
  
Investigation Type 2013 2014 2015 2016 2017 2018 
Regulatory Violation 18 27 31 71 90 95 
General Practice Standards 16 17 33 63 76 66 
Failure to Fill Rx Properly 28 28 21 17 27 44 
Drug Violation 32 62 61 95 58 22 
Inspectional Deficiencies 21 7 17 18 16 22 
Other 27 52 19 19 6 6 
SRE (Serious Reportable Event) 0 0 0 0 2 4 
 
What this means:  The Board continued to see an increase in “Regulatory Violations” due to the 
self-reporting of continuing education deficiencies.  The Board saw an increase in “Failure to Fill 
Rx Properly” (see Appendix F).  Board staff also continued to monitor controlled substance loss 
reports, or “Drug Violations”.  The implementation of Policy 16-02 extended time to report a loss 
of controlled substances, so that a pharmacy may properly investigate circumstances prior to 
reporting. This resulted in a decrease of these Investigations. 
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Appendix H:  Other Investigation Types7 
 
 
 
Investigation Type 2013 2014 2015 2016 2017 2018 
Abnormal Report 0 0 40 37 13 3 
Confidentiality Violation 1 1 2 5 4 3 
Practice While Impaired 0 1 0 0 2 2 
Unlicensed Practice 0 0 0 0 1 2 
Criminal Activity 0 1 6 8 2 1 
Discipline in Another Jurisdiction 0 0 0 0 2 1 
Compounding Pharmacy OSR
8
 0 0 0 0 1 1 
Unprofessional Conduct 8 7 3 2 1 1 
Unethical Conduct 1 0 1 2 0 1 
Inadequate/Fraudulent Documentation 0 0 1 1 0 1 
                                                 
7
 The following complaint types have been removed from this report as they have not been used since 2015 or earlier: 
Good Moral Character Evaluation, Request for Inspection, and Substance Abuse. 
8
 Compounding Pharmacy Out of Specification Report (OSR) 
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Delay in Therapy 0 0 11 4 1 0 
Practicing Beyond Scope 0 0 1 2 0 0 
 
What this means:  The Board conducted a limited number of Investigations classified in the 
categories on the chart above. Most matters that are characterized in these categories are opened 
as Complaints, but these Investigations were opened to collect further information to determine if 
a Complaint is warranted.  The decrease in investigations classified as “Abnormal Reports” is 
attributed to the implementation of staff action policy 16-04, which allows for Above Action 
Level reports to be resolved at the triage level.  This policy includes a requirement for Board Staff 
to submit a report of above action level statistics to the Board on a monthly basis.  
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Appendix I:  Investigations by License Type 
 
Investigations by License Type  2013 2014 2015 2016 2017 2018 
Drug Store 123 177 202 261 199 161 
Pharmacist 21 20 35 68 82 104 
Pharmacy Technician 10 11 5 9 12 6 
Pharmacy Intern 2 1 1 1 1 2 
Nuclear Pharmacy 0 0 1 3 5 1 
Wholesale Distributor 1 2 3 2 3 1 
Unlicensed 33 2 0 0 0 0 
Pharmacy Technician in Training 0 0 0 0 0 0 
 
What this means:  In keeping with historical figures, Drug Stores had the highest number of 
Investigations of all license types.  Investigations typically start against Drug Stores, as the Drug 
Store maintains and holds the records surrounding the alleged incidents.  Once information is 
obtained from the drug store in question and reviewed, related companion cases are opened 
against any individual licensees involved in the alleged incidents whose conduct constitutes a 
violation of applicable regulation or statute.  The rise in pharmacist Investigations is attributed to 
continuing education deficiency self-disclosures, as mentioned in Appendix G. 
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Appendix J:  Formal Complaint Status Types 
 
 
Status 2013 2014 2015 2016 2017 2018 
Pending Investigation 55 42 45 84 36 19 
Pending Board Action 102 58 17 70 32 13 
Pending Board Counsel 84 126 64 31 24 20 
Pending Prosecution 48 42 43 30 26 23 
Pending Hearing Officer 0 4 1 9 5 9 
Pending Administrative Hold 0 0 0 1 0 0 
Closed 151 284 267 197 328 127 
Total 440 556 437 422 451 211 
 
  
0
50
100
150
200
250
300
350
Pending
Investigation
Pending Board
Action
Pending Board
Counsel
Pending
Prosecution
Pending
Hearing Officer
Pending
Administrative
Hold
Closed
N
u
m
b
e
r 
o
f 
C
o
m
p
la
in
ts
 
Status 
Complaint Status 
2013
2014
2015
2016
2017
2018
19 
 
 
What this means:  Most importantly, the 2018 data shows that the Board continued to process all 
Complaints that were waiting to be heard by the Board.  At the end of 2018, Complaints that are 
updated to Pending Board Action are routinely heard at the next scheduled Board meeting, unless 
they are delayed by extenuating circumstances beyond Board or staff control.  For example, many 
of the Complaints that have been Pending Board Action for longer than a month have not been 
heard due to lack of quorum caused by recusals.  In 2018, while Complaint closure volume 
decreased due to overall decreased volume, the closure rate is consistent with the closure rate of 
prior years.
9
  Complaints are processed in the expedited formal Complaint processing system 
established in 2014.  
                                                 
9
  Year – Closure Rate: 2015 – 61%; 2016 – 46%; 2017 – 72%; 2018 – 60% 
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Appendix K:  Formal Complaint Dispositions 
 
 
 
Disposition 2013 2014 2015 2016 2017 2018 
Resulting in Discipline 51 74 74 70 108 58 
Resulting in Non-Discipline 26 78 83 13 37 13 
Dismissed 69 120 110 114 183 56 
 
What this means:  In keeping with the continued implementation of a Just Culture (see Appendix 
F), in 2018, licensees were given the opportunity to respond to Complaints related to medication 
errors by completing continuing education credits in anticipation of the Board hearing their 
respective Complaint.  This opportunity has resulted in many of the Complaints being dismissed 
for discipline not warranted, and a significant decrease in Complaints resulting in non-disciplinary 
action.  The Complaints resulting in discipline are attributed to Complaints for inspectional 
deficiencies and drug violations resulting from record keeping discrepancies or diversion, which 
are areas that the Board is monitoring closely. 
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Appendix L:  Most Common Complaint Types 
 
 
 
Complaint Type 2013 2014 2015 2016 2017 2018 
Drug Violation 54 73 70 100 153 93 
Inspectional Deficiencies 65 60 79 79 53 32 
Failure to Fill Rx Properly 162 229 142 128 140 27 
Regulatory Violation 23 47 48 41 49 23 
General Practice Standards 52 27 18 16 16 14 
Serious Reportable Event (SRE) 18 62 53 30 19 10 
 
What this means:  In 2018, the most common Complaint type was “Drug Violation”.  Cases in 
this category often are the result of a reported loss of controlled substances, diversions or 
record keeping deficiencies.  In 2018, the Board opened Complaints on pharmacies that had 
reportable confirmed losses of controlled substances. .  Complaints for “Failure to Fill RX 
Properly,” showed a decrease.  This is the result of this complaint type increasingly being 
handled as an investigation (see appendix G). A continued and significant field presence in 
2018 uncovered inspectional deficiencies and regulatory violations resulting in formal 
Complaints.  
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Appendix M:  Other Complaint Types10 
 
 
 
Complaint Type 2013 2014 2015 2016 2017 2018 
Criminal Activity 2 1 1 9 9 5 
DOR Notice 1 1 2 2 5 2 
Other 9 5 4 3 2 1 
Discipline in Another Jurisdiction 25 25 8 4 1 1 
Unethical Conduct 1 0 2 4 1 1 
Unprofessional Conduct 2 0 0 0 1 1 
Unlicensed Practice 5 2 4 3 0 1 
Confidentiality Violation 5 4 2 2 1 0 
Practice While Impaired 1 1 0 0 1 0 
Delay in Therapy 0 0 0 1 0 0 
 
  
                                                 
10
 The following complaint types have been removed from this report as they have not been used since 2015 or 
earlier: Breach of Contract, Abnormal Report, Criminal Conviction, General Misconduct, and Substance Abuse. 
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What this means:  In 2018, the total number of “Criminal Activity” Complaints decreased.  The 
Board saw suspension notices from the Department of Revenue decrease since 2017, which 
remains equivalent to prior years.  By law, the Board is required to suspend the license of the 
individual named after receiving such a notice from the Department of Revenue.  These 
Complaints are handled through an administrative process overseen by the Board’s Counsel.  
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Appendix N:  Complaints by License Type 
 
 
 
Complaints by License Type  2013 2014 2015 2016 2017 2018 
Drug Store 151 195 194 203 237 137 
Pharmacist 176 238 165 133 133 48 
Pharmacy Technician 104 100 71 76 72 19 
Pharmacy Intern 3 9 5 6 4 3 
Wholesale Distributor 2 2 2 2 4 3 
Pharmacy Technician in Training 0 0 0 0 0 1 
Nuclear Pharmacy 0 0 0 1 1 0 
Unlicensed 2 1 0 1 0 0 
 
What this means:  In 2018, most Complaints opened by the Board were against Drug Stores.  As 
described in Appendix I for Investigations, Complaints also typically begin with Drug Stores and 
after additional information is received, related companion cases may be opened against 
individual licensees involved in the alleged incident(s).  2018 marked the commencement of 
licensure for Pharmacy Technicians in Training, and the first complaint of this type was opened. 
Complaint volume for all other license types, decreased in 2018. 
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Appendix O:  Collaboration with Outside Agencies 
 
 
 
 
Collaboration with Outside Agencies 2013 2014 2015 2016 2017 2018 
Complaints 42 60 49 67 77 41 
Investigations 20 26 16 25 38 18 
 
 
What this means:  In 2018, the data demonstrates a continued effort of staff to collaborate with 
outside agencies in Complaints and Investigations.  The Board and Board staff continue to forge 
strong relationships with our local, state and federal partners and will collaborate on cases where 
doing so is in the best interest of public health and safety. 
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Appendix P:  Case Openings 
 
 
 
 
 
What this means:  In 2018, Complaint openings have decreased, while Investigation openings 
maintained a similar average with prior years.  This is attributed to increased licensee 
understanding of statutes, regulations, and policies, resulting from an increased field presence by 
Board Investigators. The decrease may also be attributed to the implementation of Policy 16-02, 
which extended time to report a loss of controlled substances, resulting in these matters remaining 
triage files until the loss is confirmed or located prior to the close of the reporting timeframe.  
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Appendix Q:  Case Closings 
 
 
 
 
 
 
 
 
 
 
 
What this means:  In 2018, the Board achieved a 49.8% increase since 2013 in Complaint and 
Investigation closings.  Furthermore, in 2018, the Board closed 183 fewer cases than in 2017. 
This is attributed to the completion of backlogged Complaint volume from previous years and the 
expedited processing of new cases since 2014.  Investigators and Board staff continue to work 
diligently to conduct Investigations and process cases expeditiously. 
0
50
100
150
200
250
300
350
Complaints Investigations
N
u
m
b
e
r 
o
f 
C
a
s
e
s
 
Type of Case 
Case Closings 
2013
2014
2015
2016
2017
2018
Closings 2013 2014 2015 2016 2017 2018 
Complaints 151 284 267 197 328 119 
Investigations 76 136 144 227 195 221 
